TRLV · Trulieve Cannabis Corp. · Financials
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $1.14B | $1.18B | $1.19B | $1.13B | $1.22B | $931.93M | $521.53M | $252.82M | |
| $461.65M | $470.01M | $470.75M | $540.57M | $529.1M | $365.36M | $135.12M | $60.98M | |
| $677.39M | $711.17M | $715.75M | $588.63M | $689.13M | $566.57M | $386.42M | $191.84M | |
| — | 60.21% | 60.32% | 52.13% | 56.57% | 60.8% | 74.09% | 75.88% | |
| — | — | $257.72M | $240.17M | $277.56M | $211.91M | $119.4M | $59.35M | |
| — | — | $252.74M | $146M | $169.47M | $99.46M | $36.06M | $14.07M | |
| $431.99M | $445.21M | $510.45M | $386.16M | — | — | — | — | |
| — | $83.3M | $82.2M | $80.4M | $81.7M | $27.7M | $2.99M | $1.8M | |
| $114.34M | $117.63M | $112.81M | $109.83M | $116.38M | $45.79M | $12.6M | $5.08M | |
| $954.66M | $567.67M | $617.97M | $810.24M | $638.96M | $362.52M | $168.11M | $78.57M | |
| -$277.26M | $143.5M | $97.78M | -$221.61M | $50.17M | $204.05M | $218.3M | $113.27M | |
| — | 12.15% | 8.24% | -19.63% | 4.12% | 21.9% | 41.86% | 44.8% | |
| -$162.92M | $261.13M | $210.59M | -$111.79M | $166.55M | $249.84M | $230.9M | $118.35M | |
| $56.85M | $63.45M | $62.19M | $81.57M | $73.42M | $29.12M | $20.24M | $9.05M | |
| $10.96M | — | — | $6.16M | $1.63M | $205K | — | — | |
| -$48.67M | -$52.02M | -$55.07M | -$62.92M | -$69.4M | -$27.8M | -$60.85M | -$9.59M | |
| -$325.93M | $91.47M | $42.71M | -$284.54M | -$19.24M | $176.25M | $157.45M | $103.68M | |
| $144.75M | $208.11M | $197.59M | $151.36M | $163.38M | $145.72M | $94.45M | $50.59M | |
| -$476.16M | -$122.25M | -$160.58M | -$533.14M | -$252.73M | $17.45M | $63M | $53.1M | |
| — | -10.35% | -13.53% | -47.21% | -20.75% | 1.87% | 12.08% | 21% | |
| — | -$5.87M | -$5.47M | -$5.15M | -$3.99M | -$587K | $0 | $0 | |
| -$473.3M | -$116.38M | -$155.11M | -$526.8M | -$246.06M | $18.03M | $63M | $53.1M | |
| USD/shares | — | -$0.58 | -$0.79 | -$2.28 | -$0.95 | $0.22 | $0.55 | $0.48 |
| USD/shares | — | -$0.58 | -$0.79 | -$2.28 | -$0.95 | $0.21 | $0.53 | $0.46 |
| shares | — | 191.32M | 189.99M | 188.97M | 188M | 139.37M | 113.57M | 110.21M |
| shares | — | 191.32M | 189.99M | 188.97M | 188M | 146.76M | 118.33M | 115.32M |
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 44 similar-size Drug Manufacturers - Specialty & Generic companies (of 100 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Retail | $1,110,437,000 | $1,128,877,000 | $1,083,545,000 | $1,158,475,000 | $869,707,000 | $520,217,000 |
| Wholesale and Other | $70,743,000 | $57,613,000 | $45,648,000 | $59,754,000 | — | — |
| Wholesale Licensing and Other | — | — | — | — | — | $1,316,000 |
| Wholesale | — | — | — | — | $61,137,000 | — |
| License | — | — | — | — | $1,090,000 | — |